The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Afutuzumab Market Research Report 2025
Synopsis
Afutuzumab, more commonly known as obinutuzumab is a humanized type II monoclonal antibody against CD20 (coded for by MS4A1 for the treatment of Chronic lymphocytic leukemia, CLL. It may have more direct antibody-dependent cell-mediated cytotoxicity and possibly more direct cytotoxicity than previously available type I antibodies such as rituximab and ofatumumab which have more complement-dependent cytotoxicity.
The global Afutuzumab market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Afutuzumab is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Afutuzumab is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Afutuzumab include BOC Sciences, Carbosynth, Roche Group, TargetMol Chemicals, Wonda Science, Absin Bioscience, Chunchuang (Wuhan) Technology, Hubei Kele Fine Chemical and Jiangxi Ruiweier Biotechnology, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Afutuzumab, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Afutuzumab.
Report Scope
The Afutuzumab market size, estimations, and forecasts are provided in terms of sales volume (Kg) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Afutuzumab market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Afutuzumab manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
BOC Sciences
Carbosynth
Roche Group
TargetMol Chemicals
Wonda Science
Absin Bioscience
Chunchuang (Wuhan) Technology
Hubei Kele Fine Chemical
Jiangxi Ruiweier Biotechnology
Qingdao Jieshikang Biotechnology
Shanghai Biochempartner
Shanghai Macklin Biochemical
Shanghai Qiming Biotechnology
Shanghai Saimai Biotechnology
Shanghai Shize Biological Technology
Shanghai Yifei Biotechnology
Shanghai Yu'ang Chemical
Tianmen Hengchang Chemical
Wuhan Sunrise Technology Development
Wuhan Yingnuo Pharmaceutical Technology
Segment by Type
Patent
Generic
Segment by Application
Chronic Lymphocytic Leukemia
Follicular Lymphoma
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Afutuzumab manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Afutuzumab in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Afutuzumab, more commonly known as obinutuzumab is a humanized type II monoclonal antibody against CD20 (coded for by MS4A1 for the treatment of Chronic lymphocytic leukemia, CLL. It may have more direct antibody-dependent cell-mediated cytotoxicity and possibly more direct cytotoxicity than previously available type I antibodies such as rituximab and ofatumumab which have more complement-dependent cytotoxicity.
The global Afutuzumab market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Afutuzumab is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Afutuzumab is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Afutuzumab include BOC Sciences, Carbosynth, Roche Group, TargetMol Chemicals, Wonda Science, Absin Bioscience, Chunchuang (Wuhan) Technology, Hubei Kele Fine Chemical and Jiangxi Ruiweier Biotechnology, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Afutuzumab, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Afutuzumab.
Report Scope
The Afutuzumab market size, estimations, and forecasts are provided in terms of sales volume (Kg) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Afutuzumab market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Afutuzumab manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
BOC Sciences
Carbosynth
Roche Group
TargetMol Chemicals
Wonda Science
Absin Bioscience
Chunchuang (Wuhan) Technology
Hubei Kele Fine Chemical
Jiangxi Ruiweier Biotechnology
Qingdao Jieshikang Biotechnology
Shanghai Biochempartner
Shanghai Macklin Biochemical
Shanghai Qiming Biotechnology
Shanghai Saimai Biotechnology
Shanghai Shize Biological Technology
Shanghai Yifei Biotechnology
Shanghai Yu'ang Chemical
Tianmen Hengchang Chemical
Wuhan Sunrise Technology Development
Wuhan Yingnuo Pharmaceutical Technology
Segment by Type
Patent
Generic
Segment by Application
Chronic Lymphocytic Leukemia
Follicular Lymphoma
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Afutuzumab manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Afutuzumab in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Afutuzumab Market Overview
1.1 Product Overview and Scope of Afutuzumab
1.2 Afutuzumab Segment by Type
1.2.1 Global Afutuzumab Market Value Comparison by Type (2024-2030)
1.2.2 Patent
1.2.3 Generic
1.3 Afutuzumab Segment by Application
1.3.1 Global Afutuzumab Market Value by Application: (2024-2030)
1.3.2 Chronic Lymphocytic Leukemia
1.3.3 Follicular Lymphoma
1.4 Global Afutuzumab Market Size Estimates and Forecasts
1.4.1 Global Afutuzumab Revenue 2019-2030
1.4.2 Global Afutuzumab Sales 2019-2030
1.4.3 Global Afutuzumab Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Afutuzumab Market Competition by Manufacturers
2.1 Global Afutuzumab Sales Market Share by Manufacturers (2019-2024)
2.2 Global Afutuzumab Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Afutuzumab Average Price by Manufacturers (2019-2024)
2.4 Global Afutuzumab Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Afutuzumab, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Afutuzumab, Product Type & Application
2.7 Afutuzumab Market Competitive Situation and Trends
2.7.1 Afutuzumab Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Afutuzumab Players Market Share by Revenue
2.7.3 Global Afutuzumab Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Afutuzumab Retrospective Market Scenario by Region
3.1 Global Afutuzumab Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Afutuzumab Global Afutuzumab Sales by Region: 2019-2030
3.2.1 Global Afutuzumab Sales by Region: 2019-2024
3.2.2 Global Afutuzumab Sales by Region: 2025-2030
3.3 Global Afutuzumab Global Afutuzumab Revenue by Region: 2019-2030
3.3.1 Global Afutuzumab Revenue by Region: 2019-2024
3.3.2 Global Afutuzumab Revenue by Region: 2025-2030
3.4 North America Afutuzumab Market Facts & Figures by Country
3.4.1 North America Afutuzumab Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Afutuzumab Sales by Country (2019-2030)
3.4.3 North America Afutuzumab Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Afutuzumab Market Facts & Figures by Country
3.5.1 Europe Afutuzumab Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Afutuzumab Sales by Country (2019-2030)
3.5.3 Europe Afutuzumab Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Afutuzumab Market Facts & Figures by Country
3.6.1 Asia Pacific Afutuzumab Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Afutuzumab Sales by Country (2019-2030)
3.6.3 Asia Pacific Afutuzumab Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Afutuzumab Market Facts & Figures by Country
3.7.1 Latin America Afutuzumab Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Afutuzumab Sales by Country (2019-2030)
3.7.3 Latin America Afutuzumab Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Afutuzumab Market Facts & Figures by Country
3.8.1 Middle East and Africa Afutuzumab Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Afutuzumab Sales by Country (2019-2030)
3.8.3 Middle East and Africa Afutuzumab Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Afutuzumab Sales by Type (2019-2030)
4.1.1 Global Afutuzumab Sales by Type (2019-2024)
4.1.2 Global Afutuzumab Sales by Type (2025-2030)
4.1.3 Global Afutuzumab Sales Market Share by Type (2019-2030)
4.2 Global Afutuzumab Revenue by Type (2019-2030)
4.2.1 Global Afutuzumab Revenue by Type (2019-2024)
4.2.2 Global Afutuzumab Revenue by Type (2025-2030)
4.2.3 Global Afutuzumab Revenue Market Share by Type (2019-2030)
4.3 Global Afutuzumab Price by Type (2019-2030)
5 Segment by Application
5.1 Global Afutuzumab Sales by Application (2019-2030)
5.1.1 Global Afutuzumab Sales by Application (2019-2024)
5.1.2 Global Afutuzumab Sales by Application (2025-2030)
5.1.3 Global Afutuzumab Sales Market Share by Application (2019-2030)
5.2 Global Afutuzumab Revenue by Application (2019-2030)
5.2.1 Global Afutuzumab Revenue by Application (2019-2024)
5.2.2 Global Afutuzumab Revenue by Application (2025-2030)
5.2.3 Global Afutuzumab Revenue Market Share by Application (2019-2030)
5.3 Global Afutuzumab Price by Application (2019-2030)
6 Key Companies Profiled
6.1 BOC Sciences
6.1.1 BOC Sciences Corporation Information
6.1.2 BOC Sciences Description and Business Overview
6.1.3 BOC Sciences Afutuzumab Sales, Revenue and Gross Margin (2019-2024)
6.1.4 BOC Sciences Afutuzumab Product Portfolio
6.1.5 BOC Sciences Recent Developments/Updates
6.2 Carbosynth
6.2.1 Carbosynth Corporation Information
6.2.2 Carbosynth Description and Business Overview
6.2.3 Carbosynth Afutuzumab Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Carbosynth Afutuzumab Product Portfolio
6.2.5 Carbosynth Recent Developments/Updates
6.3 Roche Group
6.3.1 Roche Group Corporation Information
6.3.2 Roche Group Description and Business Overview
6.3.3 Roche Group Afutuzumab Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Roche Group Afutuzumab Product Portfolio
6.3.5 Roche Group Recent Developments/Updates
6.4 TargetMol Chemicals
6.4.1 TargetMol Chemicals Corporation Information
6.4.2 TargetMol Chemicals Description and Business Overview
6.4.3 TargetMol Chemicals Afutuzumab Sales, Revenue and Gross Margin (2019-2024)
6.4.4 TargetMol Chemicals Afutuzumab Product Portfolio
6.4.5 TargetMol Chemicals Recent Developments/Updates
6.5 Wonda Science
6.5.1 Wonda Science Corporation Information
6.5.2 Wonda Science Description and Business Overview
6.5.3 Wonda Science Afutuzumab Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Wonda Science Afutuzumab Product Portfolio
6.5.5 Wonda Science Recent Developments/Updates
6.6 Absin Bioscience
6.6.1 Absin Bioscience Corporation Information
6.6.2 Absin Bioscience Description and Business Overview
6.6.3 Absin Bioscience Afutuzumab Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Absin Bioscience Afutuzumab Product Portfolio
6.6.5 Absin Bioscience Recent Developments/Updates
6.7 Chunchuang (Wuhan) Technology
6.6.1 Chunchuang (Wuhan) Technology Corporation Information
6.6.2 Chunchuang (Wuhan) Technology Description and Business Overview
6.6.3 Chunchuang (Wuhan) Technology Afutuzumab Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Chunchuang (Wuhan) Technology Afutuzumab Product Portfolio
6.7.5 Chunchuang (Wuhan) Technology Recent Developments/Updates
6.8 Hubei Kele Fine Chemical
6.8.1 Hubei Kele Fine Chemical Corporation Information
6.8.2 Hubei Kele Fine Chemical Description and Business Overview
6.8.3 Hubei Kele Fine Chemical Afutuzumab Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Hubei Kele Fine Chemical Afutuzumab Product Portfolio
6.8.5 Hubei Kele Fine Chemical Recent Developments/Updates
6.9 Jiangxi Ruiweier Biotechnology
6.9.1 Jiangxi Ruiweier Biotechnology Corporation Information
6.9.2 Jiangxi Ruiweier Biotechnology Description and Business Overview
6.9.3 Jiangxi Ruiweier Biotechnology Afutuzumab Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Jiangxi Ruiweier Biotechnology Afutuzumab Product Portfolio
6.9.5 Jiangxi Ruiweier Biotechnology Recent Developments/Updates
6.10 Qingdao Jieshikang Biotechnology
6.10.1 Qingdao Jieshikang Biotechnology Corporation Information
6.10.2 Qingdao Jieshikang Biotechnology Description and Business Overview
6.10.3 Qingdao Jieshikang Biotechnology Afutuzumab Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Qingdao Jieshikang Biotechnology Afutuzumab Product Portfolio
6.10.5 Qingdao Jieshikang Biotechnology Recent Developments/Updates
6.11 Shanghai Biochempartner
6.11.1 Shanghai Biochempartner Corporation Information
6.11.2 Shanghai Biochempartner Afutuzumab Description and Business Overview
6.11.3 Shanghai Biochempartner Afutuzumab Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Shanghai Biochempartner Afutuzumab Product Portfolio
6.11.5 Shanghai Biochempartner Recent Developments/Updates
6.12 Shanghai Macklin Biochemical
6.12.1 Shanghai Macklin Biochemical Corporation Information
6.12.2 Shanghai Macklin Biochemical Afutuzumab Description and Business Overview
6.12.3 Shanghai Macklin Biochemical Afutuzumab Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Shanghai Macklin Biochemical Afutuzumab Product Portfolio
6.12.5 Shanghai Macklin Biochemical Recent Developments/Updates
6.13 Shanghai Qiming Biotechnology
6.13.1 Shanghai Qiming Biotechnology Corporation Information
6.13.2 Shanghai Qiming Biotechnology Afutuzumab Description and Business Overview
6.13.3 Shanghai Qiming Biotechnology Afutuzumab Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Shanghai Qiming Biotechnology Afutuzumab Product Portfolio
6.13.5 Shanghai Qiming Biotechnology Recent Developments/Updates
6.14 Shanghai Saimai Biotechnology
6.14.1 Shanghai Saimai Biotechnology Corporation Information
6.14.2 Shanghai Saimai Biotechnology Afutuzumab Description and Business Overview
6.14.3 Shanghai Saimai Biotechnology Afutuzumab Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Shanghai Saimai Biotechnology Afutuzumab Product Portfolio
6.14.5 Shanghai Saimai Biotechnology Recent Developments/Updates
6.15 Shanghai Shize Biological Technology
6.15.1 Shanghai Shize Biological Technology Corporation Information
6.15.2 Shanghai Shize Biological Technology Afutuzumab Description and Business Overview
6.15.3 Shanghai Shize Biological Technology Afutuzumab Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Shanghai Shize Biological Technology Afutuzumab Product Portfolio
6.15.5 Shanghai Shize Biological Technology Recent Developments/Updates
6.16 Shanghai Yifei Biotechnology
6.16.1 Shanghai Yifei Biotechnology Corporation Information
6.16.2 Shanghai Yifei Biotechnology Afutuzumab Description and Business Overview
6.16.3 Shanghai Yifei Biotechnology Afutuzumab Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Shanghai Yifei Biotechnology Afutuzumab Product Portfolio
6.16.5 Shanghai Yifei Biotechnology Recent Developments/Updates
6.17 Shanghai Yu'ang Chemical
6.17.1 Shanghai Yu'ang Chemical Corporation Information
6.17.2 Shanghai Yu'ang Chemical Afutuzumab Description and Business Overview
6.17.3 Shanghai Yu'ang Chemical Afutuzumab Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Shanghai Yu'ang Chemical Afutuzumab Product Portfolio
6.17.5 Shanghai Yu'ang Chemical Recent Developments/Updates
6.18 Tianmen Hengchang Chemical
6.18.1 Tianmen Hengchang Chemical Corporation Information
6.18.2 Tianmen Hengchang Chemical Afutuzumab Description and Business Overview
6.18.3 Tianmen Hengchang Chemical Afutuzumab Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Tianmen Hengchang Chemical Afutuzumab Product Portfolio
6.18.5 Tianmen Hengchang Chemical Recent Developments/Updates
6.19 Wuhan Sunrise Technology Development
6.19.1 Wuhan Sunrise Technology Development Corporation Information
6.19.2 Wuhan Sunrise Technology Development Afutuzumab Description and Business Overview
6.19.3 Wuhan Sunrise Technology Development Afutuzumab Sales, Revenue and Gross Margin (2019-2024)
6.19.4 Wuhan Sunrise Technology Development Afutuzumab Product Portfolio
6.19.5 Wuhan Sunrise Technology Development Recent Developments/Updates
6.20 Wuhan Yingnuo Pharmaceutical Technology
6.20.1 Wuhan Yingnuo Pharmaceutical Technology Corporation Information
6.20.2 Wuhan Yingnuo Pharmaceutical Technology Afutuzumab Description and Business Overview
6.20.3 Wuhan Yingnuo Pharmaceutical Technology Afutuzumab Sales, Revenue and Gross Margin (2019-2024)
6.20.4 Wuhan Yingnuo Pharmaceutical Technology Afutuzumab Product Portfolio
6.20.5 Wuhan Yingnuo Pharmaceutical Technology Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Afutuzumab Industry Chain Analysis
7.2 Afutuzumab Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Afutuzumab Production Mode & Process
7.4 Afutuzumab Sales and Marketing
7.4.1 Afutuzumab Sales Channels
7.4.2 Afutuzumab Distributors
7.5 Afutuzumab Customers
8 Afutuzumab Market Dynamics
8.1 Afutuzumab Industry Trends
8.2 Afutuzumab Market Drivers
8.3 Afutuzumab Market Challenges
8.4 Afutuzumab Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Afutuzumab Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Afutuzumab Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Afutuzumab Market Competitive Situation by Manufacturers in 2023
Table 4. Global Afutuzumab Sales (Kg) of Key Manufacturers (2019-2024)
Table 5. Global Afutuzumab Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Afutuzumab Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Afutuzumab Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Afutuzumab Average Price (US$/Kg) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Afutuzumab, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Afutuzumab, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Afutuzumab, Product Type & Application
Table 12. Global Key Manufacturers of Afutuzumab, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Afutuzumab by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Afutuzumab as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Afutuzumab Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Afutuzumab Sales by Region (2019-2024) & (Kg)
Table 18. Global Afutuzumab Sales Market Share by Region (2019-2024)
Table 19. Global Afutuzumab Sales by Region (2025-2030) & (Kg)
Table 20. Global Afutuzumab Sales Market Share by Region (2025-2030)
Table 21. Global Afutuzumab Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Afutuzumab Revenue Market Share by Region (2019-2024)
Table 23. Global Afutuzumab Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Afutuzumab Revenue Market Share by Region (2025-2030)
Table 25. North America Afutuzumab Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Afutuzumab Sales by Country (2019-2024) & (Kg)
Table 27. North America Afutuzumab Sales by Country (2025-2030) & (Kg)
Table 28. North America Afutuzumab Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Afutuzumab Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Afutuzumab Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Afutuzumab Sales by Country (2019-2024) & (Kg)
Table 32. Europe Afutuzumab Sales by Country (2025-2030) & (Kg)
Table 33. Europe Afutuzumab Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Afutuzumab Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Afutuzumab Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Afutuzumab Sales by Region (2019-2024) & (Kg)
Table 37. Asia Pacific Afutuzumab Sales by Region (2025-2030) & (Kg)
Table 38. Asia Pacific Afutuzumab Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Afutuzumab Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Afutuzumab Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Afutuzumab Sales by Country (2019-2024) & (Kg)
Table 42. Latin America Afutuzumab Sales by Country (2025-2030) & (Kg)
Table 43. Latin America Afutuzumab Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Afutuzumab Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Afutuzumab Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Afutuzumab Sales by Country (2019-2024) & (Kg)
Table 47. Middle East & Africa Afutuzumab Sales by Country (2025-2030) & (Kg)
Table 48. Middle East & Africa Afutuzumab Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Afutuzumab Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Afutuzumab Sales (Kg) by Type (2019-2024)
Table 51. Global Afutuzumab Sales (Kg) by Type (2025-2030)
Table 52. Global Afutuzumab Sales Market Share by Type (2019-2024)
Table 53. Global Afutuzumab Sales Market Share by Type (2025-2030)
Table 54. Global Afutuzumab Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Afutuzumab Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Afutuzumab Revenue Market Share by Type (2019-2024)
Table 57. Global Afutuzumab Revenue Market Share by Type (2025-2030)
Table 58. Global Afutuzumab Price (US$/Kg) by Type (2019-2024)
Table 59. Global Afutuzumab Price (US$/Kg) by Type (2025-2030)
Table 60. Global Afutuzumab Sales (Kg) by Application (2019-2024)
Table 61. Global Afutuzumab Sales (Kg) by Application (2025-2030)
Table 62. Global Afutuzumab Sales Market Share by Application (2019-2024)
Table 63. Global Afutuzumab Sales Market Share by Application (2025-2030)
Table 64. Global Afutuzumab Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Afutuzumab Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Afutuzumab Revenue Market Share by Application (2019-2024)
Table 67. Global Afutuzumab Revenue Market Share by Application (2025-2030)
Table 68. Global Afutuzumab Price (US$/Kg) by Application (2019-2024)
Table 69. Global Afutuzumab Price (US$/Kg) by Application (2025-2030)
Table 70. BOC Sciences Corporation Information
Table 71. BOC Sciences Description and Business Overview
Table 72. BOC Sciences Afutuzumab Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2019-2024)
Table 73. BOC Sciences Afutuzumab Product
Table 74. BOC Sciences Recent Developments/Updates
Table 75. Carbosynth Corporation Information
Table 76. Carbosynth Description and Business Overview
Table 77. Carbosynth Afutuzumab Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2019-2024)
Table 78. Carbosynth Afutuzumab Product
Table 79. Carbosynth Recent Developments/Updates
Table 80. Roche Group Corporation Information
Table 81. Roche Group Description and Business Overview
Table 82. Roche Group Afutuzumab Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2019-2024)
Table 83. Roche Group Afutuzumab Product
Table 84. Roche Group Recent Developments/Updates
Table 85. TargetMol Chemicals Corporation Information
Table 86. TargetMol Chemicals Description and Business Overview
Table 87. TargetMol Chemicals Afutuzumab Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2019-2024)
Table 88. TargetMol Chemicals Afutuzumab Product
Table 89. TargetMol Chemicals Recent Developments/Updates
Table 90. Wonda Science Corporation Information
Table 91. Wonda Science Description and Business Overview
Table 92. Wonda Science Afutuzumab Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2019-2024)
Table 93. Wonda Science Afutuzumab Product
Table 94. Wonda Science Recent Developments/Updates
Table 95. Absin Bioscience Corporation Information
Table 96. Absin Bioscience Description and Business Overview
Table 97. Absin Bioscience Afutuzumab Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2019-2024)
Table 98. Absin Bioscience Afutuzumab Product
Table 99. Absin Bioscience Recent Developments/Updates
Table 100. Chunchuang (Wuhan) Technology Corporation Information
Table 101. Chunchuang (Wuhan) Technology Description and Business Overview
Table 102. Chunchuang (Wuhan) Technology Afutuzumab Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2019-2024)
Table 103. Chunchuang (Wuhan) Technology Afutuzumab Product
Table 104. Chunchuang (Wuhan) Technology Recent Developments/Updates
Table 105. Hubei Kele Fine Chemical Corporation Information
Table 106. Hubei Kele Fine Chemical Description and Business Overview
Table 107. Hubei Kele Fine Chemical Afutuzumab Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2019-2024)
Table 108. Hubei Kele Fine Chemical Afutuzumab Product
Table 109. Hubei Kele Fine Chemical Recent Developments/Updates
Table 110. Jiangxi Ruiweier Biotechnology Corporation Information
Table 111. Jiangxi Ruiweier Biotechnology Description and Business Overview
Table 112. Jiangxi Ruiweier Biotechnology Afutuzumab Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2019-2024)
Table 113. Jiangxi Ruiweier Biotechnology Afutuzumab Product
Table 114. Jiangxi Ruiweier Biotechnology Recent Developments/Updates
Table 115. Qingdao Jieshikang Biotechnology Corporation Information
Table 116. Qingdao Jieshikang Biotechnology Description and Business Overview
Table 117. Qingdao Jieshikang Biotechnology Afutuzumab Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2019-2024)
Table 118. Qingdao Jieshikang Biotechnology Afutuzumab Product
Table 119. Qingdao Jieshikang Biotechnology Recent Developments/Updates
Table 120. Shanghai Biochempartner Corporation Information
Table 121. Shanghai Biochempartner Description and Business Overview
Table 122. Shanghai Biochempartner Afutuzumab Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2019-2024)
Table 123. Shanghai Biochempartner Afutuzumab Product
Table 124. Shanghai Biochempartner Recent Developments/Updates
Table 125. Shanghai Macklin Biochemical Corporation Information
Table 126. Shanghai Macklin Biochemical Description and Business Overview
Table 127. Shanghai Macklin Biochemical Afutuzumab Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2019-2024)
Table 128. Shanghai Macklin Biochemical Afutuzumab Product
Table 129. Shanghai Macklin Biochemical Recent Developments/Updates
Table 130. Shanghai Qiming Biotechnology Corporation Information
Table 131. Shanghai Qiming Biotechnology Description and Business Overview
Table 132. Shanghai Qiming Biotechnology Afutuzumab Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2019-2024)
Table 133. Shanghai Qiming Biotechnology Afutuzumab Product
Table 134. Shanghai Qiming Biotechnology Recent Developments/Updates
Table 135. Shanghai Saimai Biotechnology Corporation Information
Table 136. Shanghai Saimai Biotechnology Description and Business Overview
Table 137. Shanghai Saimai Biotechnology Afutuzumab Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2019-2024)
Table 138. Shanghai Saimai Biotechnology Afutuzumab Product
Table 139. Shanghai Saimai Biotechnology Recent Developments/Updates
Table 140. Shanghai Shize Biological Technology Corporation Information
Table 141. Shanghai Shize Biological Technology Description and Business Overview
Table 142. Shanghai Shize Biological Technology Afutuzumab Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2019-2024)
Table 143. Shanghai Shize Biological Technology Afutuzumab Product
Table 144. Shanghai Shize Biological Technology Recent Developments/Updates
Table 145. Shanghai Yifei Biotechnology Corporation Information
Table 146. Shanghai Yifei Biotechnology Description and Business Overview
Table 147. Shanghai Yifei Biotechnology Afutuzumab Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2019-2024)
Table 148. Shanghai Yifei Biotechnology Afutuzumab Product
Table 149. Shanghai Yifei Biotechnology Recent Developments/Updates
Table 150. Shanghai Yu'ang Chemical Corporation Information
Table 151. Shanghai Yu'ang Chemical Description and Business Overview
Table 152. Shanghai Yu'ang Chemical Afutuzumab Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2019-2024)
Table 153. Shanghai Yu'ang Chemical Afutuzumab Product
Table 154. Shanghai Yu'ang Chemical Recent Developments/Updates
Table 155. Tianmen Hengchang Chemical Corporation Information
Table 156. Tianmen Hengchang Chemical Description and Business Overview
Table 157. Tianmen Hengchang Chemical Afutuzumab Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2019-2024)
Table 158. Tianmen Hengchang Chemical Afutuzumab Product
Table 159. Tianmen Hengchang Chemical Recent Developments/Updates
Table 160. Wuhan Sunrise Technology Development Corporation Information
Table 161. Wuhan Sunrise Technology Development Description and Business Overview
Table 162. Wuhan Sunrise Technology Development Afutuzumab Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2019-2024)
Table 163. Wuhan Sunrise Technology Development Afutuzumab Product
Table 164. Wuhan Sunrise Technology Development Recent Developments/Updates
Table 165. Wuhan Yingnuo Pharmaceutical Technology Corporation Information
Table 166. Wuhan Yingnuo Pharmaceutical Technology Description and Business Overview
Table 167. Wuhan Yingnuo Pharmaceutical Technology Afutuzumab Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2019-2024)
Table 168. Wuhan Yingnuo Pharmaceutical Technology Afutuzumab Product
Table 169. Wuhan Yingnuo Pharmaceutical Technology Recent Developments/Updates
Table 170. Key Raw Materials Lists
Table 171. Raw Materials Key Suppliers Lists
Table 172. Afutuzumab Distributors List
Table 173. Afutuzumab Customers List
Table 174. Afutuzumab Market Trends
Table 175. Afutuzumab Market Drivers
Table 176. Afutuzumab Market Challenges
Table 177. Afutuzumab Market Restraints
Table 178. Research Programs/Design for This Report
Table 179. Key Data Information from Secondary Sources
Table 180. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Afutuzumab
Figure 2. Global Afutuzumab Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Afutuzumab Market Share by Type in 2023 & 2030
Figure 4. Patent Product Picture
Figure 5. Generic Product Picture
Figure 6. Global Afutuzumab Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Afutuzumab Market Share by Application in 2023 & 2030
Figure 8. Chronic Lymphocytic Leukemia
Figure 9. Follicular Lymphoma
Figure 10. Global Afutuzumab Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 11. Global Afutuzumab Market Size (2019-2030) & (US$ Million)
Figure 12. Global Afutuzumab Sales (2019-2030) & (Kg)
Figure 13. Global Afutuzumab Average Price (US$/Kg) & (2019-2030)
Figure 14. Afutuzumab Report Years Considered
Figure 15. Afutuzumab Sales Share by Manufacturers in 2023
Figure 16. Global Afutuzumab Revenue Share by Manufacturers in 2023
Figure 17. The Global 5 and 10 Largest Afutuzumab Players: Market Share by Revenue in 2023
Figure 18. Afutuzumab Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 19. Global Afutuzumab Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 20. North America Afutuzumab Sales Market Share by Country (2019-2030)
Figure 21. North America Afutuzumab Revenue Market Share by Country (2019-2030)
Figure 22. United States Afutuzumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 23. Canada Afutuzumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 24. Europe Afutuzumab Sales Market Share by Country (2019-2030)
Figure 25. Europe Afutuzumab Revenue Market Share by Country (2019-2030)
Figure 26. Germany Afutuzumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 27. France Afutuzumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. U.K. Afutuzumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. Italy Afutuzumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. Russia Afutuzumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Asia Pacific Afutuzumab Sales Market Share by Region (2019-2030)
Figure 32. Asia Pacific Afutuzumab Revenue Market Share by Region (2019-2030)
Figure 33. China Afutuzumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Japan Afutuzumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. South Korea Afutuzumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. India Afutuzumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. Australia Afutuzumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. China Taiwan Afutuzumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Indonesia Afutuzumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Thailand Afutuzumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Malaysia Afutuzumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Latin America Afutuzumab Sales Market Share by Country (2019-2030)
Figure 43. Latin America Afutuzumab Revenue Market Share by Country (2019-2030)
Figure 44. Mexico Afutuzumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Brazil Afutuzumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Argentina Afutuzumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Middle East & Africa Afutuzumab Sales Market Share by Country (2019-2030)
Figure 48. Middle East & Africa Afutuzumab Revenue Market Share by Country (2019-2030)
Figure 49. Turkey Afutuzumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Saudi Arabia Afutuzumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. UAE Afutuzumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Global Sales Market Share of Afutuzumab by Type (2019-2030)
Figure 53. Global Revenue Market Share of Afutuzumab by Type (2019-2030)
Figure 54. Global Afutuzumab Price (US$/Kg) by Type (2019-2030)
Figure 55. Global Sales Market Share of Afutuzumab by Application (2019-2030)
Figure 56. Global Revenue Market Share of Afutuzumab by Application (2019-2030)
Figure 57. Global Afutuzumab Price (US$/Kg) by Application (2019-2030)
Figure 58. Afutuzumab Value Chain
Figure 59. Afutuzumab Production Process
Figure 60. Channels of Distribution (Direct Vs Distribution)
Figure 61. Distributors Profiles
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
